Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects
An Open-Label Safety and Tolerability Study of Immediate-Release and Extended-Release Oxymorphone in Opioid-Tolerant Pediatric Subjects With Chronic Pain.
Sponsor: Endo Pharmaceuticals
Terminated
Terminated new protocol developed which incorporated Pharmacokinetics
Other terminated trials from Endo Pharmaceuticals
Other Chronic Pain trials with similar outcome
A PHASE3 clinical study on Chronic Pain, this trial is terminated or withdrawn. The trial is conducted by Endo Pharmaceuticals and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Endo Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .